Univercells Technologies

sells the scale-X platform, a fixed-bed perfusion bioreactor line scaling from a 0.5 m² scale-X nexo research system to a 600 m² scale-X nitro commercial-manufacturing configuration for vaccine and viral-vector production, engineered to overcome the scale-up limitations of traditional stirred-tank culture.

Country
Belgium
Commercial scale-X fixed-bed perfusion, 0.5 m² (nexo) to 600 m² (nitro) eu
Coverage
CNEUUS
automation-robotics—✓—
upstream-bioreactors✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Founded2020univercellstech.com
HeadquartersNivelles, Belgiumdonaldsonlifesciences.com · univercellstech.com
Production siteNivelles, Belgiumunivercellstech.com
CapacityBioreactor line scaling from 0.5 m² (nexo) to 200–600 m² (nitro)univercellstech.com
CertificationBioreactors are gamma irradiated and supplied with a full validation guide for GMP conditionsunivercellstech.com
Regulatory approvalTechnology used for clinical material production under GMP following FDA & EMA authority; NevoLine platform enables compliance to 21CFR part 11univercellstech.com
Headcount62.5 FTEs as of 2025; 68 employees as of July 2026companyweb.be
RevenueApproximately €10 million (calendar year 2022); €6,090,844 (2025 financial statements)companyweb.be · univercellstech.com

Independent sources: companyweb.be · donaldsonlifesciences.com

Technologies
NameClusterRisk
High-cell-density culture systemsupstream-bioreactorsLow→
Seed-train automation systemsautomation-roboticsHigh→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.